This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Fracture Risk Assessment Tool | |
|---|---|
| Name | Fracture Risk Assessment Tool |
| Developer | World Health Organization / Sheffield team |
| Released | 2008 |
| Latest release | ongoing |
| Operating system | Cross-platform |
| Platform | Web, desktop, mobile |
| License | Open access |
Fracture Risk Assessment Tool is a clinical prediction model designed to estimate an individual’s absolute risk of osteoporotic fracture over a defined time horizon. It integrates demographic, clinical, and imaging-related inputs to output probability estimates that inform management decisions in musculoskeletal medicine and public health. The tool has been incorporated into guidelines, decision support systems, and research across multiple countries and institutions.
The tool combines epidemiological data with clinical risk factors to quantify fracture probability; it links risk factors such as age, sex, prior fracture, and bone mineral density with outcome rates derived from population studies. It was developed to aid clinicians, policymakers, and researchers at organizations including the World Health Organization, National Institutes of Health, National Health Service (England), and other national agencies. Implementation environments range from primary care clinics affiliated with Mayo Clinic and Cleveland Clinic to academic centers like Harvard Medical School, University of Oxford, and University of Sheffield.
Development emerged from collaborations among researchers at institutions including University of Sheffield, World Health Organization, and cohorts from Framingham Heart Study, Rotterdam Study, and Study of Osteoporotic Fractures. Early statistical modeling drew on survival analyses informed by data from national registries such as Swedish National Patient Register and cohorts curated by National Cancer Institute–affiliated investigators. Subsequent iterations incorporated inputs from professional societies like the International Osteoporosis Foundation, American Association of Clinical Endocrinologists, and Endocrine Society.
The model uses multivariable regression calibrated to incidence and competing mortality rates observed in large population datasets including those from Centers for Disease Control and Prevention, National Center for Health Statistics, and national cohorts in United Kingdom, United States, Sweden, and Spain. Key predictors were selected through epidemiologic criteria evident in studies by investigators affiliated with Johns Hopkins University, Massachusetts General Hospital, and Karolinska Institutet. Bone mineral density inputs reference standards from densitometry methods used at centers such as Mayo Clinic and manufacturers like GE Healthcare and Hologic. Statistical validation involved techniques popularized in methodological textbooks from authors at University of Pennsylvania and Stanford University.
Clinical adoption has been recommended or endorsed by bodies including the National Osteoporosis Foundation, Royal Osteoporosis Society, European Calcified Tissue Society, American College of Physicians, and national health agencies like NHS England and the Canadian Task Force on Preventive Health Care. The tool is integrated into electronic health record workflows at systems such as Epic Systems and Cerner Corporation and is cited in guidelines produced at institutions like Johns Hopkins Medicine and Cleveland Clinic. It informs treatment thresholds referenced in guidance from British National Formulary committees and panels convened by World Health Organization technical working groups.
Validation studies have been conducted using datasets from cohorts such as the Framingham Heart Study, Rotterdam Study, Australian Longitudinal Study on Women’s Health, and national registries managed by Statistics Netherlands and Statistics Sweden. Performance metrics reported in peer-reviewed publications from journals associated with The Lancet, New England Journal of Medicine, BMJ, and Journal of Bone and Mineral Research include discrimination (c-statistics) and calibration across diverse populations. Multicenter evaluations involved teams from University of Toronto, Monash University, Karolinska Institutet, and McGill University.
Critiques have arisen from investigators at institutions like University College London, Imperial College London, and Yale School of Medicine regarding calibration in underrepresented populations, including cohorts in India, China, and sub-Saharan Africa where baseline fracture incidence differs from derivation samples. Other limitations highlighted by researchers at Columbia University and King’s College London include imprecision when applied to patients with secondary osteoporosis conditions treated at centers such as Mayo Clinic specialty clinics or to those on novel therapies studied at National Institutes of Health–funded trials. Debates in editorials in journals linked to BMJ and The Lancet focus on thresholds for treatment and the social implications of population screening recommendations from agencies like National Health Service (Scotland).
Several country- and population-specific adaptations have been produced by organizations including Canadian Task Force on Preventive Health Care, Australian Government Department of Health, and research groups at University of Auckland and Seoul National University. Related risk models and tools developed by academic and industry groups include algorithms from FRAMINGHAM-linked investigators, fracture risk calculators embedded in decision aids from International Osteoporosis Foundation, and alternative models proposed by teams at Queen Mary University of London and University of California, San Francisco. Integration efforts have linked the tool with fracture liaison services coordinated by hospitals such as Guy's and St Thomas' NHS Foundation Trust and Royal Infirmary of Edinburgh.
Category:Medical assessment tools